Archives

75-year-old fast food chain closing 200 restaurants, fights to survive

When people get more conservative with spending, it hurts restaurants that lack a true following. Some people love chains such as Chipotle, Chick-fil-A, Starbucks, and even McDonald’s. They view spending money at those brands as a reasonable indulgence, something they may not truly be able to afford, but a treat they deserve. It’s something that […]

Weekly Review

At Brown University, in an exam review session for an economics course, a man opened fire, killing two and injuring nine, in what is at least the seventy-fifth school shooting in the United States this year.1 2 “The one thing that gave me comfort was, like, statistically, it’s practically impossible for this to ever happen […]

In a banner year for biopharma, here are the best industry CEOs of 2025 – statnews.com

In a banner year for biopharma, here are the best industry CEOs of 2025  statnews.com Fierce Biotech’s Rotten Tomatoes of 2025  Fierce Biotech The Year in Biology  Quanta Magazine Biotechnology Advances in 2025 Highlight GLP-1 Receptor Agonists for Metabolic Disorders and Radiopharmaceuticals in Precision Oncology  geneonline.com Biotech in 2025: what truly mattered this year  Labiotech.eu

Pharmaceuticals, Vol. 18, Pages 1896: Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process

Pharmaceuticals, Vol. 18, Pages 1896: Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process Pharmaceuticals doi: 10.3390/ph18121896 Authors: Rolan R. Shaifutdinov Maria V. Sinegubova Ivan I. Vorobiev Polina E. Prokhorova Alexey B. Podkorytov Nadezhda A. Orlova Background: Dulaglutide, a GLP-1-IgG4 Fc fusion, is a long-acting GLP-1 receptor agonist […]

2026 Healthcare Executive Predictions: Why the AI “Pilot Era” Is Officially Over

If the last two years were defined by the breathless hype of experimentation, 2026 marks the healthcare industry’s decisive transition from “flashy, one-off experiments” to “top-down programs designed for measurable impact”. Across the digital health landscape, executives agree that the “pilot era is ending,” with the focus shifting entirely to systems that can be “governed, […]

Popular weight-loss drugs may lower cancer risk, finds large study

Exciting new findings indicate that GLP-1 weight-loss medications might dramatically reduce the likelihood of 10 types of cancer linked to obesity for patients with type 2 diabetes, outperforming insulin. However, there’s no observed benefit for postmenopausal breast or thyroid cancers.

Integrating Prescription Intelligence and CMEs Into the Prescribing Workflow

Healthcare IT leaders are finding innovative ways to address one of medicine’s challenges: the exponential growth of clinical knowledge that physicians must navigate daily. In our recent interview, we hear from Julia Vu, Pharm.D., Vice President, GTM North America at Elsevier and Colin Banas, MD, MHA, Chief Medical Officer at DrFirst about their partnership to […]

Eli Lilly or Merck: Where Should Investors Put Their Money?

Eli Lilly LLY and Merck MRK are both major global pharmaceutical companies with blockbuster drug portfolios and deep pipelines. Both companies have a strong presence in oncology, immunology and neuroscience areas. Lilly boasts a leading presence in cardiometabolic health, with GLP-1 drugs Mounjaro and Zepbound accounting for around 36% of the company’s total revenues. Oncology drives […]

Is PepsiCo’s Innovation Pipeline Strong Enough to Reaccelerate Growth?

PepsiCo, Inc.’s PEP innovation strategy is a core growth engine. The company’s innovation pipeline is robust, increasingly well-aligned with the evolving consumer preferences, especially the shift toward health-oriented beverages and snacks, functional products and clean-label reformulations. PEP’s strong focus on innovation, particularly around permissible and functional product benefits, along with ongoing portfolio reshaping, optimized price-pack […]